Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer

Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer

Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modulators of tumor cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, macitentan, on human ovarian cancer cells, SKO...

Full description

Bibliographic Details
Main Authors: Sun-Jin Kim, Jang Seong Kim, Seung Wook Kim, Emily Brantley, Seok Joong Yun, Junqin He, Marva Maya, Fahao Zhang, Qiuyu Wu, François Lehembre, Urs Regenass, Isaiah J. Fidler
Format: Article
Language:English
Published: Elsevier 2011-02-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558611800552

Internet

http://www.sciencedirect.com/science/article/pii/S1476558611800552

Similar Items